Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

@article{Liu2014CombinationCA,
  title={Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.},
  author={Joyce Liu and William Thomas Barry and Michael J. Birrer and Jung-Min Lee and Ronald J. Buckanovich and Gwen F. Fleming and B. J. Rimel and Mary Kathleen Buss and Sreenivasa R Nattam and Jean A. Hurteau and Weixiu Luo and Philippa Quy and Christin Whalen and Lisa Obermayer and Hang Seop Lee and Eric P. Winer and Elise C. Kohn and S Percy Ivy and Ursula A. Matulonis},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 11},
  pages={
          1207-14
        }
}
BACKGROUND Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 146 CITATIONS, ESTIMATED 44% COVERAGE

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

  • Cancer management and research
  • 2019
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

PARP inhibition in ovarian cancer: state of the science.

  • Gynecologic oncology
  • 2015
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The development of PARP inhibitors in ovarian cancer: from bench to bedside

  • British Journal of Cancer
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 23 Citations per year from 2017 through 2019